Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary CholangitisBusiness Wire • 12/13/24
Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024Business Wire • 12/09/24
Longest Follow-Up Data Reported for Kite's Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival BenefitsBusiness Wire • 12/09/24
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASHBusiness Wire • 12/08/24
Gilead Sciences, Inc. (GILD) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)Seeking Alpha • 12/04/24
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADCZacks Investment Research • 12/04/24
Gilead Sciences, Inc. (GILD) Piper Sandler 36th Annual Healthcare Conference (Transcript)Seeking Alpha • 12/03/24
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor TargetBusiness Wire • 12/03/24
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 ResultsBusiness Wire • 11/27/24
The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.Business Wire • 11/22/24
Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)Seeking Alpha • 11/20/24
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary CholangitisBusiness Wire • 11/15/24
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV GlasgowBusiness Wire • 11/13/24
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and PipelineBusiness Wire • 11/12/24